Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human 'de novo' colorectal carcinomas.
PMID 11384100 · PMC2363669 · British journal of cancer · 2001 · 7 claims · 6 setups
BGP positive foci occur sporadically in the transitional mucosa adjacent to 'de novo' colorectal carcinomas in all cases studied
-
Full-text index only
The current state of proteomics in GI oncology.
PMID 19104933 · PMC3045515 · Digestive diseases and sciences · 2009 · 8 claims · 8 setups
More than 130 exploratory proteomic studies have defined candidate biomarkers in serum, GI fluids, or cancer tissue for GI oncology
-
Full-text index only
Characterisation and protein expression profiling of annexins in colorectal cancer.
PMID 18071363 · PMC2361450 · British journal of cancer · 2008 · 7 claims · 5 setups
Annexins A1, A2, A4 and A11 are overexpressed in primary colorectal cancer compared with normal colon
-
Full-text index only
Proteomic approaches to cancer biomarkers.
PMID 19931265 · PMC2873613 · Gastroenterology · 2010 · 8 claims · 8 setups
Combining abundant-protein depletion, offline fractionation, and subproteome (e.g., glycoproteome) enrichment with 2D LC-MS/MS increases the dynamic range and depth of blood proteome analysis for biomarker discovery.
-
Full-text index only
A new era for proteomics research?
PMID 19014405 · PMC2614486 · Genome biology · 2008 · 8 claims · 8 setups
Refined mass spectrometry instrumentation and software now make whole-proteome coverage of model organisms in a single experiment conceivable
-
Full-text index only
Contribution of oncoproteomics to cancer biomarker discovery.
PMID 17407558 · PMC1852117 · Molecular cancer · 2007 · 6 claims · 8 setups
Oncoproteomic biomarker panels (2-DE/MS-based) show higher sensitivity and specificity than currently used single tumor markers across multiple cancer types (Table 1)